


PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁷ : C12Q 1/44, 1/68, C12P 19/34, C07H 21/04, C12N 9/22		A1	(11) International Publication Number: WO 00/15833
			(43) International Publication Date: 23 March 2000 (23.03.00)
(21) International Application Number: PCT/US99/21092		Five Moore Drive, P.O. Box 13398, Research Triangle Park, NC 27709 (US).	
(22) International Filing Date: 14 September 1999 (14.09.99)		(74) Agents: LEVY, David, J.; Glaxo Wellcome Inc., Five Moore Drive, P.O. Box 13398, Research Triangle Park, NC 27709-3398 (US) et al.	
(30) Priority Data: 60/100,491 16 September 1998 (16.09.98) US 60/100,704 17 September 1998 (17.09.98) US		(81) Designated States: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).	
(63) Related by Continuation (CON) or Continuation-in-Part (CIP) to Earlier Applications US 60/100,491 (CIP) Filed on 16 September 1998 (16.09.98) US 60/100,704 (CIP) Filed on 17 September 1998 (17.09.98)		Published With international search report. Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.	
(71) Applicant (for all designated States except US): GLAXO GROUP LIMITED [GB/GB]; Glaxo Wellcome House, Berkeley Avenue, Greenford, Middlesex UB6 0NN (GB).			
(72) Inventors; and (75) Inventors/Applicants (for US only): BURNS, Daniel, Keith [US/US]; Glaxo Wellcome Inc., Five Moore Drive, P.O. Box 13398, Research Triangle Park, NC 27709 (US). WEINER, Michael, Phillip [US/US]; Glaxo Wellcome Inc.,			

(54) Title: MULTIPLE SEQUENCING METHOD

(57) Abstract

The present invention provides a method for identifying a nucleic acid utilizing a run-off sequencing reaction of a relatively short portion of the nucleic acid. The method can be utilized, for example, to identify an EST from only a small portion of the EST and in an analysis of nucleotide polymorphisms. The figure depicts an untreated and a BpmI-treated sequencing reaction.

M.H


PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁷ : C12Q 1/44, 1/68, C12P 19/34, C07H 21/04, C12N 9/22		A1	(11) International Publication Number: WO 00/15833
			(43) International Publication Date: 23 March 2000 (23.03.00)
(21) International Application Number: PCT/US99/21092		Five Moore Drive, P.O. Box 13398, Research Triangle Park, NC 27709 (US).	
(22) International Filing Date: 14 September 1999 (14.09.99)		(74) Agents: LEVY, David, J.; Glaxo Wellcome Inc., Five Moore Drive, P.O. Box 13398, Research Triangle Park, NC 27709-3398 (US) et al.	
(30) Priority Data: 60/100,491 16 September 1998 (16.09.98) US 60/100,704 17 September 1998 (17.09.98) US		(81) Designated States: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).	
(63) Related by Continuation (CON) or Continuation-in-Part (CIP) to Earlier Applications US 60/100,491 (CIP) Filed on 16 September 1998 (16.09.98) US 60/100,704 (CIP) Filed on 17 September 1998 (17.09.98)		Published With international search report. Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.	
(71) Applicant (for all designated States except US): GLAXO GROUP LIMITED [GB/GB]; Glaxo Wellcome House, Berkeley Avenue, Greenford, Middlesex UB6 0NN (GB).			
(72) Inventors; and (75) Inventors/Applicants (for US only): BURNS, Daniel, Keith [US/US]; Glaxo Wellcome Inc., Five Moore Drive, P.O. Box 13398, Research Triangle Park, NC 27709 (US). WEINER, Michael, Phillip [US/US]; Glaxo Wellcome Inc.,			

(54) Title: MULTIPLE SEQUENCING METHOD



(57) Abstract

The present invention provides a method for identifying a nucleic acid utilizing a run-off sequencing reaction of a relatively short portion of the nucleic acid. The method can be utilized, for example, to identify an EST from only a small portion of the EST and in an analysis of nucleotide polymorphisms. The figure depicts an untreated and a BpmI-treated sequencing reaction.

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakhstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US99/21092

C (Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	BRENNER et al. DNA fingerprinting by sampled sequencing. Proceedings of the National Academy of Sciences USA. November 1989, Vol. 86, pages 8902-8906, see entire reference.	6-12

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US99/21092

B. FIELDS SEARCHED

Electronic data bases consulted (Name of data base and where practicable terms used):

USPAT, WPI, JPO, EPO, Medline, CAPLUS, EMBASE, BIOSIS, LIFESCI, SCISEARCH

search terms: sequencing, nucleic acid, dna, polynucleotide, multiple, multi, dual, sequential, run, load, restriction enzyme, restriction endonuclease, BpmI, FokI, BsgI, Eco57I, BcgI, Mmel, AlwI, Alw26I, BbsI, BbvI, BsaI, BsmI, BsmAI, BspMI, Bst71I, EarI, Esp3I, HgaI, HphI, Ksp632I, MbolI, MnlI, PstI, SfaNI

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US99/21092

A. CLASSIFICATION OF SUBJECT MATTER

IPC(7) : C12Q 1/44, 1/68; C12P 19/34; C07H 21/04; C12N 9/22

US CL : 435/6, 19, 91.2, 91.5, 199; 536/24.2

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

U.S. : 435/6, 19, 91.2, 91.5, 199; 536/24.2

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

Please See Extra Sheet.

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	US 5,695,937 (KINZLER et al) 09 December 1997, see entire reference, especially col. 5, lines 51-60, col. 8, lines 1-18, claims 38-42.	13
A	US 5,449,604 A (SCHELLENBERG et al) 12 September 1995, especially col. 36, lines 39-45.	1-12
A	US 5,374,527 A (GROSSMAN et al) 20 December 1994, especially col. 3, line 67-col. 4, line 2, col. 12, lines 29-30, col. 13, lines 56-59.	1-12
A	US 5,710,000 A (SAPOLSKY et al) 20 January 1998, see entire reference.	6-12



Further documents are listed in the continuation of Box C.



See patent family annex.

* Special categories of cited documents:	*T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
A document defining the general state of the art which is not considered to be of particular relevance	*X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
E earlier document published on or after the international filing date	*Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
L document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	*&* document member of the same patent family
O document referring to an oral disclosure, use, exhibition or other means	
P document published prior to the international filing date but later than the priority date claimed	

Date of the actual completion of the international search

01 DECEMBER 1999

Date of mailing of the international search report

04 FEB 2000

Name and mailing address of the ISA/US
Commissioner of Patents and Trademarks
Box PCT
Washington, D.C. 20231

Authorized officer

DIANA B. JOHANNSEN

Examination No. 7031 405.3730

Telephone No. (202) 306-0100

PATENT COOPERATION TREATY

PCT

INTERNATIONAL SEARCH REPORT

(PCT Article 18 and Rules 43 and 44)

Applicant's or agent's file reference PU3562WO	FOR FURTHER ACTION see Notification of Transmittal of International Search Report (Form PCT/ISA/220) as well as, where applicable, item 5	
International application No. PCT/US99/21092	International filing date (<i>day/month/year</i>) 14 SEPTEMBER 1999	(Earliest) Priority Date (<i>day/month/year</i>) 16 SEPTEMBER 1998
Applicant GLAXO GROUP LIMITED		

This international search report has been prepared by this International Searching Authority and is transmitted to the applicant according to Article 18. A copy is being transmitted to the International Bureau.

This international search report consists of a total of 5 sheets.

☒ It is also accompanied by a copy of each prior art document cited in this report.

1. ☐ Certain claims were found unsearchable (See Box I).

2. ☐ Unity of invention is lacking (See Box II).

3. ☐ The international application contains disclosure of a nucleotide and/or amino acid sequence listing and the international search was carried out on the basis of the sequence listing

☐ filed with the international application.
☐ furnished by the applicant separately from the international application,

☐ but not accompanied by a statement to the effect that it did not include matter going beyond the disclosure in the international application as filed.

☐ transcribed by this Authority.

4. With regard to the title,

☒ the text is approved as submitted by the applicant.
☐ the text has been established by this Authority to read as follows:

5. With regard to the abstract,

☐ the text is approved as submitted by the applicant.
☒ the text has been established, according to Rule 38.2(b), by this Authority as it appears in Box III. The applicant may, within one month from the date of mailing of this international search report, submit comments to this Authority.

6. The figure of the drawings to be published with the abstract is:
 Figure No. 1

☒ as suggested by the applicant.

☐ None of the figures.

☐ because the applicant failed to suggest a figure.
☐ because this figure better characterizes the invention.

Box III TEXT OF THE ABSTRACT (Continuation of item 5 of the first sheet)

The technical features mentioned in the abstract do not include a reference sign between parentheses (PCT Rule 8.1(d)).

ABSTRACT

The present invention provides a method for identifying a nucleic acid utilizing a run-off sequencing reaction of a relatively short portion of the nucleic acid. The method can be utilized, for example, to identify an EST from only a small portion of the EST and in an analysis of nucleotide polymorphisms. Figure 1 depicts an untreated and a BpmI-treated sequencing reaction.

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US99/21092**A. CLASSIFICATION OF SUBJECT MATTER**

IPC(7) : C12Q 1/44, 1/68; C12P 19/34; C07H 21/04; C12N 9/22

US CL : 435/6, 19, 91.2, 91.5, 199; 536/24.2

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

U.S. : 435/6, 19, 91.2, 91.5, 199; 536/24.2

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

Please See Extra Sheet.

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	US 5,695,937 (KINZLER et al) 09 December 1997, see entire reference, especially col. 5, lines 51-60, col. 8, lines 1-18, claims 38-42.	13
A	US 5,449,604 A (SCHELLENBERG et al) 12 September 1995, especially col. 36, lines 39-45.	1-12
A	US 5,374,527 A (GROSSMAN et al) 20 December 1994, especially col. 3, line 67-col. 4, line 2, col. 12, lines 29-30, col. 13, lines 56-59.	1-12
A	US 5,710,000 A (SAPOLSKY et al) 20 January 1998, see entire reference.	6-12



Further documents are listed in the continuation of Box C.



See patent family annex.

* Special categories of cited documents:	"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
"A" document defining the general state of the art which is not considered to be of particular relevance	"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
"E" earlier document published on or after the international filing date	"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	"&" document member of the same patent family
"O" document referring to an oral disclosure, use, exhibition or other means	
"P" document published prior to the international filing date but later than the priority date claimed	

Date of the actual completion of the international search

01 DECEMBER 1999

Date of mailing of the international search report

04 FEB 2000

Name and mailing address of the ISA/US
Commissioner of Patents and Trademarks
Box PCT
Washington, D.C. 20231

Authorized officer

DIANA B. JOHANNSEN

Facsimile No. (703) 305 3230

Telephone No. (703) 308 0196

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US99/21092

C (Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	<p>BRENNER et al. DNA fingerprinting by sampled sequencing. Proceedings of the National Academy of Sciences USA. November 1989, Vol. 86, pages 8902-8906, see entire reference.</p>	6-12

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US99/21092

B. FIELDS SEARCHED

Electronic data bases consulted (Name of data base and where practicable terms used):

USPAT, WPI, JPO, EPO, Medline, CAPLUS, EMBASE, BIOSIS, LIFESCI, SCISEARCH

search terms: sequencing, nucleic acid, dna, polynucleotide, multiple, multi, dual, sequential, run, load, restriction enzyme, restriction endonuclease, BpmI, FokI, BsgI, Eco57I, BcgI, MmcI, AlwI, Alw26I, BbsI, BbvI, BsaI, BsmI, BsmAI, BspMI, Bst7II, EarI, Esp3I, HgaI, HphI, Ksp632I, MboII, MnlI, PciI, SfaNI

PATENT COOPERATION TREATY

From the INTERNATIONAL SEARCHING AUTHORITY

To: DAVID J. LEVY
GLAXO WELLCOME INC.
FIVE MOORE DRIVE
PO BOX 13398
RESEARCH TRIANGLE PARK, NC 27709-3398

Docket No: PU3562W0
Attorney: ES
Paper: Art. 19 Amendment

Due Date: 3/4/00
Deadline: 4/4/00

Recorded: FEB

PCT

GLAXO-WELLCOME
I.P. DEPT.

NOTIFICATION OF TRANSMITTAL OF THE INTERNATIONAL SEARCH REPORT OR THE DECLARATION

(PCT Rule 44.1)

<p>Applicant's or agent's file reference PU3562W0</p>	<p>Date of Mailing (day/month/year) 04 FEB 2000</p>
<p>International application No. PCT/US99/21092</p>	<p>International filing date (day/month/year) 14 SEPTEMBER 1999</p>
<p>Applicant GLAXO GROUP LIMITED</p>	
<p>FOR FURTHER ACTION See paragraphs 1 and 4 below</p>	

1. ☒ The applicant is hereby notified that the international search report has been established and is transmitted herewith.
Filing of amendments and statement under Article 19:
 The applicant is entitled, if he so wishes, to amend the claims of the international application (see Rule 46):

When? The time limit for filing such amendments is normally 2 months from the date of transmittal of the international search report; however, for more details, see the notes on the accompanying sheet.

Where? Directly to the International Bureau of WIPO
 34, chemin des Colombettes
 1211 Geneva 20, Switzerland
 Facsimile No.: (41-22) 740.14.35

For more detailed instructions, see the notes on the accompanying sheet.
2. ☐ The applicant is hereby notified that no international search report will be established and that the declaration under Article 17(2)(a) to that effect is transmitted herewith.
3. ☐ With regard to the protest against payment of (an) additional fee(s) under Rule 40.2, the applicant is notified that:

☐ the protest together with the decision thereon has been transmitted to the International Bureau together with the applicant's request to forward the texts of both the protest and the decision thereon to the designated Offices.
☐ no decision has been made yet on the protest; the applicant will be notified as soon as a decision is made.
4. **Further action(s):** The applicant is reminded of the following:

Shortly after 18 months from the priority date, the international application will be published by the International Bureau. If the applicant wishes to avoid or postpone publication, a notice of withdrawal of the international application, or of the priority claim, must reach the International Bureau as provided in rules 90 bis 1 and 90 bis 3, respectively, before the completion of the technical preparations for international publication.

Within 19 months from the priority date, a demand for international preliminary examination must be filed if the applicant wishes to postpone the entry into the national phase until 30 months from the priority date (in some Offices even later).

Within 20 months from the priority date, the applicant must perform the prescribed acts for entry into the national phase before all designated Offices which have not been elected in the demand or in a later election within 19 months from the priority date or could not be elected because they are not bound by Chapter II.

Name and mailing address of the ISA/US
Commissioner of Patents and Trademarks
Box PCT
Washington, D.C. 20231
Facsimile No. (703) 305-3230

Authorized officer
DIANA B. JOHANNSEN
Telephone No. (703) 308-0196

PATENT COOPERATION TREATY

From the INTERNATIONAL SEARCHING AUTHORITY

To: DAVID J. LEVY
GLAXO WELLCOME INC.
FIVE MOORE DRIVE
PO BOX 13398
RESEARCH TRIANGLE PARK, NC 27709-3398

PCT

NOTIFICATION OF TRANSMITTAL OF THE INTERNATIONAL SEARCH REPORT OR THE DECLARATION

(PCT Rule 44.1)

Applicant's or agent's file reference PU3562WO	Date of Mailing (day/month/year) 04 FEB 2000
International application No. PCT/US99/21092	International filing date (day/month/year) 14 SEPTEMBER 1999
Applicant GLAXO GROUP LIMITED	

1. ☒ The applicant is hereby notified that the international search report has been established and is transmitted herewith.
Filing of amendments and statement under Article 19:
 The applicant is entitled, if he so wishes, to amend the claims of the international application (see Rule 46):
 When? The time limit for filing such amendments is normally 2 months from the date of transmittal of the international search report; however, for more details, see the notes on the accompanying sheet.
 Where? Directly to the International Bureau of WIPO
 34, chemin des Colombettes
 1211 Geneva 20, Switzerland
 Facsimile No.: (41-22) 740.14.35
 For more detailed instructions, see the notes on the accompanying sheet.
2. ☐ The applicant is hereby notified that no international search report will be established and that the declaration under Article 17(2)(a) to that effect is transmitted herewith.
3. ☐ With regard to the protest against payment of (an) additional fee(s) under Rule 40.2, the applicant is notified that:
 - ☐ the protest together with the decision thereon has been transmitted to the International Bureau together with the applicant's request to forward the texts of both the protest and the decision thereon to the designated Offices.
 - ☐ no decision has been made yet on the protest; the applicant will be notified as soon as a decision is made.
4. **Further action(s):** The applicant is reminded of the following:
 - Shortly after 18 months** from the priority date, the international application will be published by the International Bureau. If the applicant wishes to avoid or postpone publication, a notice of withdrawal of the international application, or of the priority claim, must reach the International Bureau as provided in rules 90 bis 1 and 90 bis 3, respectively, before the completion of the technical preparations for international publication.
 - Within 19 months** from the priority date, a demand for international preliminary examination must be filed if the applicant wishes to postpone the entry into the national phase until 30 months from the priority date (in some Offices even later).
 - Within 20 months** from the priority date, the applicant must perform the prescribed acts for entry into the national phase before all designated Offices which have not been elected in the demand or in a later election within 19 months from the priority date or could not be elected because they are not bound by Chapter II.

Name and mailing address of the ISA/US
 Commissioner of Patents and Trademarks
 Box PCT
 Washington, D.C. 20231
 Facsimile No. (703) 305-3230

Authorized officer
 DIANA B. JOHANNSEN
 Telephone No. (703) 308-0196

PATENT COOPERATION TREATY

PCT

INTERNATIONAL SEARCH REPORT

(PCT Article 18 and Rules 43 and 44)

Applicant's or agent's file reference PU3562WO	<div style="display: flex; justify-content: space-between;"> <div style="text-align: center;">FOR FURTHER ACTION</div> <div style="font-size: small;">see Notification of Transmittal of International Search Report (Form PCT/ISA/220) as well as, where applicable, item 5</div> </div>	
International application No. PCT/US99/21092	International filing date (day/month/year) 14 SEPTEMBER 1999	(Earliest) Priority Date (day/month/year) 16 SEPTEMBER 1998
Applicant GLAXO GROUP LIMITED		

This international search report has been prepared by this International Searching Authority and is transmitted to the applicant according to Article 18. A copy is being transmitted to the International Bureau.

This international search report consists of a total of 5 sheets.

☒ It is also accompanied by a copy of each prior art document cited in this report.

1. ☐ Certain claims were found unsearchable (See Box I).

2. ☐ Unity of invention is lacking (See Box II).

3. ☐ The international application contains disclosure of a nucleotide and/or amino acid sequence listing and the international search was carried out on the basis of the sequence listing

☐ filed with the international application.
☐ furnished by the applicant separately from the international application,

☐ but not accompanied by a statement to the effect that it did not include matter going beyond the disclosure in the international application as filed.

☐ transcribed by this Authority.

4. With regard to the title,

☒ the text is approved as submitted by the applicant.
☐ the text has been established by this Authority to read as follows:

5. With regard to the abstract,

☐ the text is approved as submitted by the applicant.
☒ the text has been established, according to Rule 38.2(b), by this Authority as it appears in Box III. The applicant may, within one month from the date of mailing of this international search report, submit comments to this Authority.

6. The figure of the drawings to be published with the abstract is:

Figure No. 1

☒ as suggested by the applicant.
☐ because the applicant failed to suggest a figure.
☐ because this figure better characterizes the invention.

☐ None of the figures.

Box III TEXT OF THE ABSTRACT (Continuation of item 5 of the first sheet)

The technical features mentioned in the abstract do not include a reference sign between parentheses (PCT Rule 8.1(d)).

ABSTRACT

The present invention provides a method for identifying a nucleic acid utilizing a run-off sequencing reaction of a relatively short portion of the nucleic acid. The method can be utilized, for example, to identify an EST from only a small portion of the EST and in an analysis of nucleotide polymorphisms. Figure 1 depicts an untreated and a Bpml-treated sequencing reaction.

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US99/21092**A. CLASSIFICATION OF SUBJECT MATTER**IPC(7) : C12Q 1/44, 1/68; C12P 19/34; C07H 21/04; C12N 9/22
US CL : 435/6, 19, 91.2, 91.5, 199; 536/24.2

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

U.S. : 435/6, 19, 91.2, 91.5, 199; 536/24.2

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

Please See Extra Sheet.

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	US 5,695,937 (KINZLER et al) 09 December 1997, see entire reference, especially col. 5, lines 51-60, col. 8, lines 1-18, claims 38-42.	13
A	US 5,449,604 A (SCHELLENBERG et al) 12 September 1995, especially col. 36, lines 39-45.	1-12
A	US 5,374,527 A (GROSSMAN et al) 20 December 1994, especially col. 3, line 67-col. 4, line 2, col. 12, lines 29-30, col. 13, lines 56-59.	1-12
A	US 5,710,000 A (SAPOLSKY et al) 20 January 1998, see entire reference.	6-12

☒ Further documents are listed in the continuation of Box C. ☐ See patent family annex.

* Special categories of cited documents:	*T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
A document defining the general state of the art which is not considered to be of particular relevance	*X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
E earlier document published on or after the international filing date	*Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
L document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	*Z* document member of the same patent family
O document referring to an oral disclosure, use, exhibition or other means	
P document published prior to the international filing date but later than the priority date claimed	

Date of the actual completion of the international search

01 DECEMBER 1999

Date of mailing of the international search report

04 FEB 2000

Name and mailing address of the ISA/US
Commissioner of Patents and Trademarks
Box PCT
Washington, D.C. 20231

Authorized officer

DIANA B. JOHANNSEN

Facsimile No. (703) 305-1230

Telephone No. (703) 308-0190

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US99/21092

C (Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	BRENNER et al. DNA fingerprinting by sampled sequencing. Proceedings of the National Academy of Sciences USA. November 1989, Vol. 86, pages 8902-8906, see entire reference.	6-12

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US99/21092

B. FIELDS SEARCHED

Electronic data bases consulted (Name of data base and where practicable terms used):

USPAT, WPI, JPO, EPO, Medline, CAPLUS, EMBASE, BIOSIS, LIFESCI, SCISEARCH

search terms: sequencing, nucleic acid, dna, polynucleotide, multiple, multi, dual, sequential, run, load, restriction enzyme, restriction endonuclease, BpmI, FokI, BsgI, Eco57I, BcgI, Mmel, AlwI, Alw26I, BbsI, BbvI, BsaI, BsmI, BsmAI, BspMI, Bst7II, EarI, Esp3I, HgaI, HphI, Ksp632I, MboII, MnlI, PciI, SfaNI



PATENT COOPERATION TREATY



PCT

NOTIFICATION OF ELECTION

(PCT Rule 61.2)

From the INTERNATIONAL BUREAU

To:

Assistant Commissioner for Patents
United States Patent and Trademark
Office
Box PCT
Washington, D.C. 20231
ETATS-UNIS D'AMERIQUE

in its capacity as elected Office

Date of mailing (day/month/year) 09 May 2000 (09.05.00)	
International application No. PCT/US99/21092	Applicant's or agent's file reference PU3562WO
International filing date (day/month/year) 14 September 1999 (14.09.99)	Priority date (day/month/year) 16 September 1998 (16.09.98)
Applicant BURNS, Daniel, Keith et al	

1. The designated Office is hereby notified of its election made:

☒ in the demand filed with the International Preliminary Examining Authority on:

17 March 2000 (17.03.00)

☐ in a notice effecting later election filed with the International Bureau on:

2. The election ☒ was

☐ was not

made before the expiration of 19 months from the priority date or, where Rule 32 applies, within the time limit under Rule 32.2(b).

<p>The International Bureau of WIPO 34, chemin des Colombettes 1211 Geneva 20, Switzerland</p> <p>Facsimile No.: (41-22) 740.14.35</p>	<p>Authorized officer Diana Nissen</p> <p>Telephone No.: (41-22) 338.83.38</p>
--	--

PATENT COOPERATION TREATY

PCT

INTERNATIONAL PRELIMINARY EXAMINATION REPORT

REC'D 05 JAN 2001

PCT

(PCT Article 36 and Rule 70)

Applicant's or agent's file reference PU3562WO	FOR FURTHER ACTION See Notification of Transmittal of International Preliminary Examination Report (Form PCT/IPEA/416)	
International application No. PCT/US99/21092	International filing date (day/month/year) 14 SEPTEMBER 1999	Priority date (day/month/year) 16 SEPTEMBER 1998
International Patent Classification (IPC) or national classification and IPC Please See Supplemental Sheet.		
Applicant GLAXO GROUP LIMITED		

1. This international preliminary examination report has been prepared by this International Preliminary Examining Authority and is transmitted to the applicant according to Article 36.
2. This REPORT consists of a total of 5 sheets.
☒ This report is also accompanied by ANNEXES, i.e., sheets of the description, claims and/or drawings which have been amended and are the basis for this report and/or sheets containing rectifications made before this Authority. (see Rule 70.16 and Section 607 of the Administrative Instructions under the PCT).
 These annexes consist of a total of 0 sheets.
3. This report contains indications relating to the following items:

I	<input checked="" type="checkbox"/>	Basis of the report
II	<input type="checkbox"/>	Priority
III	<input type="checkbox"/>	Non-establishment of report with regard to novelty, inventive step or industrial applicability
IV	<input type="checkbox"/>	Lack of unity of invention
V	<input checked="" type="checkbox"/>	Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability, citations and explanations supporting such statement
VI	<input type="checkbox"/>	Certain documents cited
VII	<input type="checkbox"/>	Certain defects in the international application
VIII	<input checked="" type="checkbox"/>	Certain observations on the international application

Date of submission of the demand 17 MARCH 2000	Date of completion of this report 29 NOVEMBER 2000
Name and mailing address of the IPEA/US Commissioner of Patents and Trademarks Box PCT Washington, D.C. 20231	Authorized officer <div style="display: flex; justify-content: space-between;"> <div> DIANA JOHANNSEN </div> <div style="text-align: right;"> JOYCE BRIDGERS PARALEGAL SPECIALIST CHEMICAL MATRIX </div> </div>

INTERNATIONAL PRELIMINARY EXAMINATION REPORT

International application No.

PCT/US99/21092

I. Basis of the report**1. With regard to the elements of the international application:***☒ the international application as originally filed☒ the description:pages 1-7, as originally filedpages NONE, filed with the demandpages NONE, filed with the letter of _____☒ the claims:pages 8-9, as originally filedpages NONE, as amended (together with any statement) under Article 19pages NONE, filed with the demandpages NONE, filed with the letter of _____☒ the drawings:pages 1-4, as originally filedpages NONE, filed with the demandpages NONE, filed with the letter of _____☒ the sequence listing part of the description:pages NONE, as originally filedpages NONE, filed with the demandpages NONE, filed with the letter of _____**2. With regard to the language, all the elements marked above were available or furnished to this Authority in the language in which the international application was filed, unless otherwise indicated under this item.**

These elements were available or furnished to this Authority in the following language _____ which is:

☐ the language of a translation furnished for the purposes of international search (under Rule 23.1(b)).☐ the language of publication of the international application (under Rule 48.3(b)).☐ the language of the translation furnished for the purposes of international preliminary examination (under Rules 55.2 and/or 55.3).**3. With regard to any nucleotide and/or amino acid sequence disclosed in the international application, the international preliminary examination was carried out on the basis of the sequence listing:**☐ contained in the international application in printed form.☐ filed together with the international application in computer readable form.☐ furnished subsequently to this Authority in written form.☐ furnished subsequently to this Authority in computer readable form.☐ The statement that the subsequently furnished written sequence listing does not go beyond the disclosure in the international application as filed has been furnished.☐ The statement that the information recorded in computer readable form is identical to the written sequence listing has been furnished.**4. ☒ The amendments have resulted in the cancellation of:**☒ the description, pages NONE☒ the claims, Nos. NONE☒ the drawings, sheets/fig NONE**5. ☐ This report has been drawn as if (some of) the amendments had not been made, since they have been considered to go beyond the disclosure as filed, as indicated in the Supplemental Box (Rule 70.2(c)).****

* Replacement sheets which have been furnished to the receiving Office in response to an invitation under Article 14 are referred to in this report as "originally filed" and are not annexed to this report since they do not contain amendments (Rules 70.16 and 70.17).

** Any replacement sheet containing a replacement of a sequence listing must be accompanied by a statement of the reasons for the replacement.

INTERNATIONAL PRELIMINARY EXAMINATION REPORT

International application No.

PCT/US99/21092

V. Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement**1. statement**

Novelty (N)	Claims	<u>1-13</u>	YES
	Claims	<u>NONE</u>	NO
Inventive Step (IS)	Claims	<u>1-12</u>	YES
	Claims	<u>13</u>	NO
Industrial Applicability (IA)	Claims	<u>1-13</u>	YES
	Claims	<u>NONE</u>	NO

2. citations and explanations (Rule 70.7)

Claim 13 lacks an inventive step under PCT Article 35(3) as being obvious over Kinzler et al (U.S. Patent No. 5,695,937).

The claim is drawn to a kit comprising "an enzyme that cuts at least 1 base downstream of a selected enzyme recognition site" and a "set of oligonucleotide linkers comprising a recognition site for the selected enzyme". It is noted that the intended use of a product such as a kit is not accorded patentable weight. Kinzler et al teach a method for the "serial analysis of gene expression" that requires the use of type IIS restriction enzymes and oligonucleotide linkers comprising recognition sites for type IIS restriction enzymes (see entire reference). Kinzler et al teach kits comprising sets of linkers wherein the linkers "comprise a restriction endonuclease site for cleavage of DNA at a site distant from the restriction endonuclease recognition site" (col 8, lines 1-18). Kinzler et al further teach the use of type IIS restriction enzymes, and teach that such enzymes cleave "at a site distant from or outside of the recognition site" that is "up to 20 bp away from their asymmetric recognition sites" (col 5, lines 51-60). It would have been *prima facie* obvious to one of ordinary skill in the art at the time the invention was made to have modified the kits of Kinzler et al so as to have included in the kits both oligonucleotide linkers and type IIS restriction enzymes that recognize the recognition sites present in the linkers, as well as other reagents required for the practice of Kinzler et al's method. As both the linkers and the restriction enzymes are necessary for the practice of Kinzler et al's method, an ordinary artisan would have been motivated to have made such a modification in order to have provided practitioners with all the reagents necessary to carry out the method of Kinzler et al, for the advantages of convenience, efficiency, and cost-effectiveness.

Claims 1-12 meet the criteria set out in PCT Article 35(2)-(4). Schellenberg et al (U.S. Patent No. 5,449,604) disclose "multiple loading of gel lanes" with different PCR samples (col 36, lines 39-45). Grossman et al (U.S. Patent No. 5,374,527) teach sequencing of short DNA fragments (col 3, line 67-col 4, line 2, (Continued on Supplemental Sheet.)

VIII. Certain observations on the international application

The following observations on the clarity of the claims, description, and drawings or on the question whether the claims are fully supported by the description, are made:

Claims 1-13 are objected to under PCT Rule 66.2(a)(v) as lacking clarity under PCT Article 6 because the claims are indefinite for the following reason(s).

Claims 1-6 are indefinite for failing to recite a final process step that clearly relates back to the preamble. The claims are drawn to a method "of identifying a nucleic acid", yet recite a final process step of loading sequencing reaction products onto a sequencing gel. The claims do not set forth how loading "two or more" short sequencing products allows one to "identify" a nucleic acid. Thus, it is unclear as to whether the claims are intended to be drawn to a method of loading or running a sequencing gel, or to methods of "identifying" a nucleic acid. Further, the term "identifying" is vague and indefinite, as it does not apprise one of skill in the art as to what information is to be ascertained with respect to a nucleic acid. Further, it is unclear as to whether the term "identifying" may encompass solely mental steps of "identification", or whether this language is limited to active method steps. The claims should be amended so as to clarify the actual, active process steps necessary to accomplish "identification" of a nucleic acid.

Claims 1-6 are indefinite over the recitation of the phrases "two or more short sequencing reaction products", "a first sequencing reaction product", and "a second short sequencing reaction product" in claim 1. It is unclear as to whether Applicant intends for the term "first sequencing reaction product" to refer to one of the "two or more short sequencing reaction products", or to another, additional "sequencing reaction product". Thus, it is further unclear as to whether the instant claims require one or more additional "short sequencing reaction products" in addition to the "first sequencing reaction product" and the "second short sequencing reaction product". Clarification is required.

Claims 2-3 are indefinite over the recitation of the phrase "the sequencing reaction product". Claim 1, from which claims 2-3 depend, recites more than one "sequencing reaction product". Accordingly, it is unclear as to how claim 2-3 are intended to modify claim 1 (i.e., do the claims limit each reaction product, the "first sequencing reaction product", the "second short sequencing reaction product"?).

Claims 6-12 are indefinite for failing to recite a final process step that clearly relates back to the preamble. The claims are drawn to a "method of determining the nucleotide sequence of a selected portion of a nucleic acid", yet recite a final process step of "analyzing the first sequencing reaction (Continued on Supplemental Sheet.)

INTERNATIONAL PRELIMINARY EXAMINATION REPORT

International application No.

PCT/US99/21092

Supplemental Box

(To be used when the space in any of the preceding boxes is not sufficient)

Continuation of: Boxes I - VIII

Sheet 10

CLASSIFICATION:

The International Patent Classification (IPC) and/or the National classification are as listed below:

IPC(7): C12Q 1/44, 1/68; C12P 19/34; C07H 21/04; C12N 9/22. and US Cl.: 435/6, 19, 91.2, 91.5, 199; 536/24.2

V. 2. REASONED STATEMENTS - CITATIONS AND EXPLANATIONS (Continued):

col 12, lines 29-30, col 13, lines 56-59). However, the prior art does not teach or fairly suggest loading multiple short sequencing reaction products "onto the same lanes of a sequencing gel", as required by instant claims 1-6. Sapolsky et al (U.S. Patent No. 5,710,000) disclose methods for "capturing" oligonucleotide sequences adjacent to type IIS restriction sites, and disclose that the sequences of captured oligonucleotides are preferably determined by hybridization (see entire reference). Brenner discloses a DNA fingerprinting method in which termini of fragments generated by digestion with type IIS restriction enzymes are sequenced (see entire reference). However, the prior art does not teach or fairly suggest isolating a nucleic acid from a library comprising a recognition site of an "enzyme that cuts at least 1 base downstream of the recognition site, wherein the recognition site is positioned within 1 base" of an insert, amplifying and digesting the nucleic acid, and subsequently "performing a run-off sequencing reaction utilizing a primer that hybridizes to a region" at or upstream of the recognition site, as required by instant claims 7-12.

NEW CITATIONS

NONE

VIII. CERTAIN OBSERVATIONS ON THE APPLICATION (Continued):

product". The claims do not set forth how "analyzing" a sequencing reaction product results in "determining the nucleotide sequence" of a portion of a nucleic acid, and the term "analyzing" is sufficiently broad so as to encompass solely mental steps of "analysis". Accordingly, it is not clear whether the instant claims are intended to be drawn to methods of determining the sequence of a portion of a nucleic acid, or to methods of "analyzing" a sequencing reaction product. Clarification is required.

Claims 6-13 are indefinite over the recitation of the term "selected enzyme" in claims 6, 8, and 13, and the term "selected portion" in claim 6. It is unclear as to how the term "selected" is intended to modify the structure and/or function of an enzyme or of a "portion". In other words, how would a "selected" enzyme or portion differ from an enzyme or portion? Clarification is required.


Claims 6-12 are indefinite over the recitation of the phrase "the inserts of the library" in claim 6. There is insufficient antecedent basis for this limitation in the claims, as claim 6 does not previously refer to "inserts" of a library.

Claim 7 is indefinite over the recitation of the phrase "analyzed sequentially on the same analysis run". First, it is unclear as to what is encompassed by the language "analyzed sequentially", and as to what actual methods steps might be required in order to accomplish "sequential analysis". Second, there is insufficient antecedent basis for the limitation "the same analysis run", as the claims do not previously refer to an "analysis run" or to a "same analysis run". Clarification is required.

Claim 9 is indefinite over the recitation of the limitation "the selected restriction enzyme". There is insufficient antecedent basis for this limitation in the claims, as the claims do not previously refer to a "selected restriction enzyme".

Claims 10-12 are indefinite over the recitation of the limitation "the analysis...." in each of the claims. It is unclear as to how these limitations on the "analyzing" step of the method result in or otherwise contribute to "determining the nucleotide sequence" of a portion of a nucleic acid. The claims should be amended so as to clarify what actual steps are carried out, and so as to set forth how such steps result in sequence determination.

IPSS/ES/ON



From the
INTERNATIONAL PRELIMINARY EXAMINING AUTHORITY

LOGGED IN

pdj 01/05/01

PCT

To: DAVID J. LEVY
GLAXO WELLCOME INC.
GLOBAL INTELLECTUAL PROPERTY DEPT.
FIVE MOORE DRIVE
PO BOX 13398
RESEARCH TRIANGLE PARK, NC 27709-3398

NOTIFICATION OF TRANSMITTAL OF
INTERNATIONAL PRELIMINARY
EXAMINATION REPORT

(PCT Rule 71.1)

Date of Mailing
(day/month/year)

29 DEC 2000

Applicant's or agent's file reference
PU3562WO

IMPORTANT NOTIFICATION

International application No.
PCT/US99/21092

International filing date (day/month/year)
14 SEPTEMBER 1999

Priority Date (day/month/year)
16 SEPTEMBER 1998

Applicant
GLAXO GROUP LIMITED

1. The applicant is hereby notified that this International Preliminary Examining Authority transmits herewith the international preliminary examination report and its annexes, if any, established on the international
2. A copy of the report and its annexes, if any, is being transmitted to the International Bureau for communication to all the elected Offices.
3. Where required by any of the elected Offices, the International Bureau will prepare an English translation of the report (but not of any annexes) and will transmit such translation to those Offices.
4. REMINDER

The applicant must enter the national phase before each elected Office by performing certain acts (filing translations and paying national fees) within 30 months from the priority date (or later in some Offices)(Article 39(1))(see also the reminder sent by the International Bureau with Form PCT/TB/301).

Where a translation of the international application must be furnished to an elected Office, that translation must contain a translation of any annexes to the international preliminary examination report. It is the applicant's responsibility to prepare and furnish such translation directly to each elected Office concerned.

For further details on the applicable time limits and requirements of the elected Offices, see Volume II of the PCT Applicant's Guide.

<p>Name and mailing address of the IPEA/US Commissioner of Patents and Trademarks Box PCT Washington, D.C. 20231 Facsimile No. (703) 305-3230</p>	<p>Authorized officer DIANA JOHANNSEN Telephone No. (703) 308-0196 JOYCE BRIDGERS PARALEGAL SPECIALIST CHEMICAL MATRIX</p>
---	--

IPSS/ES/IGN

PATENT COOPERATION TREATY

JAN 05 2001

PCT

WORLD INTELLECTUAL PROPERTY

INTERNATIONAL PRELIMINARY EXAMINATION REPORT

LOGGED IN

(PCT Article 36 and Rule 70)

pdy 01/05/01

Applicant's or agent's file reference PU3582WO	FOR FURTHER ACTION See Notification of Transmittal of International Preliminary Examination Report (Form PCT/IPEA/416)	
International application No. PCT/US99/21092	International filing date (day/month/year) 14 SEPTEMBER 1999	Priority date (day/month/year) 16 SEPTEMBER 1998
International Patent Classification (IPC) or national classification and IPC Please See Supplemental Sheet.		
Applicant GLAXO GROUP LIMITED		

1. This international preliminary examination report has been prepared by this International Preliminary Examining Authority and is transmitted to the applicant according to Article 36.

2. This REPORT consists of a total of 5 sheets.

☒ This report is also accompanied by ANNEXES, i.e., sheets of the description, claims and/or drawings which have been amended and are the basis for this report and/or sheets containing rectifications made before this Authority. (see Rule 70.16 and Section 607 of the Administrative Instructions under the PCT).

These annexes consist of a total of 0 sheets.

3. This report contains indications relating to the following items:

- I ☒ Basis of the report
- II ☐ Priority
- III ☐ Non-establishment of report with regard to novelty, inventive step or industrial applicability
- IV ☐ Lack of unity of invention
- V ☒ Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement
- VI ☐ Certain documents cited
- VII ☐ Certain defects in the international application
- VIII ☒ Certain observations on the international application

Date of submission of the demand 17 MARCH 2000	Date of completion of this report 29 NOVEMBER 2000
Name and mailing address of the IPEA/US Commissioner of Patents and Trademarks Box PCT Washington, D.C. 20231	Authorized officer DIANA JOHANNSEN JOYCE BRIDGERS PARALEGAL SPECIALIST CHEMICAL MATRIX
Facsimile No. (703) 305-8230	Telephone No. (703) 308-0166

INTERNATIONAL PRELIMINARY EXAMINATION REPORT

International application No.

PCT/US99/21092

I. Basis of the report**1. With regard to the elements of the international application:***

- ☒ the international application as originally filed
- ☒ the description:
pages 1-7 , as originally filed
pages NONE , filed with the demand
pages NONE , filed with the letter of _____
- ☒ the claims:
pages 8-9 , as originally filed
pages NONE , as amended (together with any statement) under Article 19
pages NONE , filed with the demand
pages NONE , filed with the letter of _____
- ☒ the drawings:
pages 1-4 , as originally filed
pages NONE , filed with the demand
pages NONE , filed with the letter of _____
- ☒ the sequence listing part of the description:
pages NONE , as originally filed
pages NONE , filed with the demand
pages NONE , filed with the letter of _____

2. With regard to the language, all the elements marked above were available or furnished to this Authority in the language in which the international application was filed, unless otherwise indicated under this item.
These elements were available or furnished to this Authority in the following language _____ which is:

- ☐ the language of a translation furnished for the purposes of international search (under Rule 23.1(b)).
- ☐ the language of publication of the international application (under Rule 48.3(b)).
- ☐ the language of the translation furnished for the purposes of international preliminary examination (under Rules 55.2 and/or 55.3).

3. With regard to any nucleotide and/or amino acid sequence disclosed in the international application, the international preliminary examination was carried out on the basis of the sequence listing:

- ☐ contained in the international application in printed form.
- ☐ filed together with the international application in computer readable form.
- ☐ furnished subsequently to this Authority in written form.
- ☐ furnished subsequently to this Authority in computer readable form.
- ☐ The statement that the subsequently furnished written sequence listing does not go beyond the disclosure in the international application as filed has been furnished.
- ☐ The statement that the information recorded in computer readable form is identical to the written sequence listing has been furnished.

4. ☒ The amendments have resulted in the cancellation of:

- ☒ the description, pages NONE
- ☒ the claims, Nos. NONE
- ☒ the drawings, sheets/fig NONE

5. ☐ This report has been drawn as if (some of) the amendments had not been made, since they have been considered to go beyond the disclosure as filed, as indicated in the Supplemental Box (Rule 70.2(c)).**

* Replacement sheets which have been furnished to the receiving Office in response to an invitation under Article 14 are referred to in this report as "originally filed" and are not annexed to this report since they do not contain amendments (Rules 70.16 and 70.17).

** Any replacement sheet containing such amendments must be referred to, underlined and annexed to this report.

INTERNATIONAL PRELIMINARY EXAMINATION REPORT

International application No.

PCT/US99/21092

V. Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement**1. statement****Novelty (N)**Claims 1-13 YESClaims NONE NO**Inventive Step (IS)**Claims 1-12 YESClaims 13 NO**Industrial Applicability (IA)**Claims 1-13 YESClaims NONE NO**2. citations and explanations (Rule 70.7)**

Claim 13 lacks an inventive step under PCT Article 33(3) as being obvious over Kinzler et al (U.S. Patent No. 5,695,937).

The claim is drawn to a kit comprising "an enzyme that cuts at least 1 base downstream of a selected enzyme recognition site" and a "set of oligonucleotide linkers comprising a recognition site for the selected enzyme". It is noted that the intended use of a product such as a kit is not accorded patentable weight. Kinzler et al teach a method for the "serial analysis of gene expression" that requires the use of type IIS restriction enzymes and oligonucleotide linkers comprising recognition sites for type IIS restriction enzymes (see entire reference). Kinzler et al teach kits comprising sets of linkers wherein the linkers "comprise a restriction endonuclease site for cleavage of DNA at a site distant from the restriction endonuclease recognition site" (col 8, lines 1-18). Kinzler et al further teach the use of type IIS restriction enzymes, and teach that such enzymes cleave "at a site distant from or outside of the recognition site" that is "up to 20 bp away from their asymmetric recognition sites" (col 5, lines 51-60). It would have been *prima facie* obvious to one of ordinary skill in the art at the time the invention was made to have modified the kits of Kinzler et al so as to have included in the kits both oligonucleotide linkers and type IIS restriction enzymes that recognize the recognition sites present in the linkers, as well as other reagents required for the practice of Kinzler et al's method. As both the linkers and the restriction enzymes are necessary for the practice of Kinzler et al's method, an ordinary artisan would have been motivated to have made such a modification in order to have provided practitioners with all the reagents necessary to carry out the method of Kinzler et al, for the advantages of convenience, efficiency, and cost-effectiveness.

Claims 1-12 meet the criteria set out in PCT Article 33(2)-(4). Schellenberg et al (U.S. Patent No. 5,449,604) disclose "multiple loading of gel lanes" with different PCR samples (col 36, lines 39-45). Grossman et al (U.S. Patent No. 5,374,527) teach sequencing of short DNA fragments (col 3, line 67-col 4, line 2, (Continued on Supplemental Sheet.)

INTERNATIONAL PRELIMINARY EXAMINATION REPORT

International application No.

PCT/US99/21092

VIII. Certain observations on the international application

The following observations on the clarity of the claims, description, and drawings or on the question whether the claims are fully supported by the description, are made:

Claims 1-15 are objected to under PCT Rule 66.2(a)(v) as lacking clarity under PCT Article 6 because the claims are indefinite for the following reason(s).

Claims 1-6 are indefinite for failing to recite a final process step that clearly relates back to the preamble. The claims are drawn to a method "of identifying a nucleic acid", yet recite a final process step of loading sequencing reaction products onto a sequencing gel. The claims do not set forth how loading "two or more" short sequencing products allows one to "identify" a nucleic acid. Thus, it is unclear as to whether the claims are intended to be drawn to a method of loading or running a sequencing gel, or to methods of "identifying" a nucleic acid. Further, the term "identifying" is vague and indefinite, as it does not apprise one of skill in the art as to what information is to be ascertained with respect to a nucleic acid. Further, it is unclear as to whether the term "identifying" may encompass solely mental steps of "identification", or whether this language is limited to active method steps. The claims should be amended so as to clarify the actual, active process steps necessary to accomplish "identification" of a nucleic acid.

Claims 1-6 are indefinite over the recitation of the phrases "two or more short sequencing reaction products", "a first sequencing reaction product", and "a second short sequencing reaction product" in claim 1. It is unclear as to whether Applicant intends for the term "first sequencing reaction product" to refer to one of the "two or more short sequencing reaction products", or to another, additional "sequencing reaction product". Thus, it is further unclear as to whether the instant claims require one or more additional "short sequencing reaction products" in addition to the "first sequencing reaction product" and the "second short sequencing reaction product". Clarification is required.

Claims 2-3 are indefinite over the recitation of the phrase "the sequencing reaction product". Claim 1, from which claims 2-3 depend, recites more than one "sequencing reaction product". Accordingly, it is unclear as to how claim 2-3 are intended to modify claim 1 (i.e., do the claims limit each reaction product, the "first sequencing reaction product", the "second short sequencing reaction product"?).

Claims 6-12 are indefinite for failing to recite a final process step that clearly relates back to the preamble. The claims are drawn to a "method of determining the nucleotide sequence of a selected portion of a nucleic acid", yet recite a final process step of "analyzing the first sequencing reaction (Continued on Supplemental Sheet.)

INTERNATIONAL PRELIMINARY EXAMINATION REPORT

International application No.

PCT/US99/21092

Supplemental Box

(To be used when the space in any of the preceding boxes is not sufficient)

Continuation of: Boxes I - VIII

Sheet 10

CLASSIFICATION:

The International Patent Classification (IPC) and/or the National classification are as listed below:

IPC(7): C12Q 1/44, 1/68; C12P 19/34; C07H 21/04; C12N 9/22. and US Cl.: 435/6, 19, 91.2, 91.5, 199; 536/24.2

V. 2. REASONED STATEMENTS - CITATIONS AND EXPLANATIONS (Continued):

col 12, lines 29-30, col 13, lines 56-59). However, the prior art does not teach or fairly suggest loading multiple short sequencing reaction products "onto the same lanes of a sequencing gel", as required by instant claims 1-6. Sapolsky et al (U.S. Patent No. 5,710,000) disclose methods for "capturing" oligonucleotide sequences adjacent to type IIS restriction sites, and disclose that the sequences of captured oligonucleotides are preferably determined by hybridization (see entire reference). Brenner discloses a DNA fingerprinting method in which termini of fragments generated by digestion with type IIS restriction enzymes are sequenced (see entire reference). However, the prior art does not teach or fairly suggest isolating a nucleic acid from a library comprising a recognition site of an "enzyme that cuts at least 1 base downstream of the recognition site, wherein the recognition site is positioned within 1 base" of an insert, amplifying and digesting the nucleic acid, and subsequently "performing a run-off sequencing reaction utilizing a primer that hybridizes to a region" at or upstream of the recognition site, as required by instant claims 7-12.

NEW CITATIONS

NONE

VIII. CERTAIN OBSERVATIONS ON THE APPLICATION (Continued):

product". The claims do not set forth how "analyzing" a sequencing reaction product results in "determining the nucleotide sequence" of a portion of a nucleic acid, and the term "analyzing" is sufficiently broad so as to encompass solely mental steps of "analysis". Accordingly, it is not clear whether the instant claims are intended to be drawn to methods of determining the sequence of a portion of a nucleic acid, or to methods of "analyzing" a sequencing reaction product. Clarification is required.

Claims 6-13 are indefinite over the recitation of the term "selected enzyme" in claims 6, 8, and 13, and the term "selected portion" in claim 6. It is unclear as to how the term "selected" is intended to modify the structure and/or function of an enzyme or of a "portion". In other words, how would a "selected" enzyme or portion differ from an enzyme or portion? Clarification is required.

Claims 6-12 are indefinite over the recitation of the phrase "the inserts of the library" in claim 6. There is insufficient antecedent basis for this limitation in the claims, as claim 6 does not previously refer to "inserts" of a library.

Claim 7 is indefinite over the recitation of the phrase "analyzed sequentially on the same analysis run". First, it is unclear as to what is encompassed by the language "analyzed sequentially", and as to what actual methods steps might be required in order to accomplish "sequential analysis". Second, there is insufficient antecedent basis for the limitation "the same analysis run", as the claims do not previously refer to an "analysis run" or to a "same analysis run". Clarification is required.

Claim 9 is indefinite over the recitation of the limitation "the selected restriction enzyme". There is insufficient antecedent basis for this limitation in the claims, as the claims do not previously refer to a "selected restriction enzyme".

Claims 10-12 are indefinite over the recitation of the limitation "the analysis...." in each of the claims. It is unclear as to how these limitations on the "analyzing" step of the method result in or otherwise contribute to "determining the nucleotide sequence" of a portion of a nucleic acid. The claims should be amended so as to clarify what actual steps are carried out, and so as to set forth how such steps result in sequence determination.

PCT

REQUEST

The undersigned requests that the present international application be processed according to the Patent Cooperation Treaty.

For receiving Office use only

International Application No.

International Filing Date

Name of receiving Office and "PCT International Application"

Applicant's or agent's file reference
(if desired) (12 characters maximum) PU3562WO

Box No. I TITLE OF INVENTION
MULTIPLEX SEQUENCING METHOD

Box No. II APPLICANT

Name and address: (Family name followed by given name; for a legal entity, full official
The address must include postal code and name of country. The country of the address indicated in this
Box is the applicant's State (that is, country) of residence if no State of residence is indicated below.)

Glaxo Group Limited
Glaxo Wellcome House
Berkeley Avenue
Greenford, Middlesex
UB6 0NN
GB

☐ This person is also inventor.

Telephone No.
919-483-2370

Facsimile No.
919-483-7988

Teleprinter No.

State (that is, country) of nationality:
GB

State (that is, country) of residence:
GB

This person is applicant ☐ all designated States ☒ all designated States except the United States of America ☐ the United States of America only ☐ the States indicated in the Supplemental Box

Box No. III FURTHER APPLICANT(S) AND/OR (FURTHER) INVENTOR(S)

Name and address: (Family name followed by given name; for a legal entity, full official designation.
The address must include postal code and name of country. The country of the address indicated in this
Box is the applicant's State (that is, country) of residence if no State of residence is indicated below.)

BURNS, Daniel Keith
c/o Glaxo Wellcome Inc.
Five Moore Drive, PO Box 13398
Research Triangle Park, NC 27709
US

This person is:

☐ applicant only

☒ applicant and inventor

☐ inventor only (If this check-box is marked, do not fill in below.)

State (that is, country) of nationality:
US

State (that is, country) of residence:
US

This person is applicant ☐ all designated States ☐ all designated States except the United States of America ☒ the United States of America only ☐ the States indicated in the Supplemental Box

☒ Further applicants and/or (further) inventors are indicated on a continuation sheet.

Box No. IV AGENT OR COMMON REPRESENTATIVE; OR ADDRESS FOR CORRESPONDENCE

The person identified below is hereby/has been appointed to act on behalf
of the applicant(s) before the competent International Authorities as:

☒ agent ☐ common representative

Name and address: (Family name followed by given name; for a legal entity, full official
designation. The address must include postal code and name of country.)

LEVY, David, J.; DADSWELL, Charles, E.; GRASSLER, Frank P.; BRINK, Robert H.;
RIEK, James P.; PRUS, Karen L.; SELBY, Elizabeth; MORGAN, Lorie Ann;
BENNETT, Virginia C.; ROGERS, Christopher P.; all Glaxo Wellcome Inc., Five
Moore Drive, PO Box 13398, Research Triangle Park, NC 27709-3398, US

Telephone No.
919-483-2370

Facsimile No.
919-483-7988

Teleprinter No.

☐ Address for correspondence: Mark this check-box where no agent or common representative is/has been appointed and the space above is used instead to indicate a special address to which correspondence should be sent.

Continuation of Box No. III FURTHER APPLICANTS AND/OR (FURTHER) INVENTOR(S)*If none of the following sub-boxes is used, this sheet is not to be included in the request.*

Name and address: (Family name followed by given name; for a legal entity, full official designation. The address must include postal code and name of country. The country of the address indicated in this Box is the applicant's State (that is, country) of residence if no State of residence is indicated below.)

WEINER, Michael Phillip
c/o Glaxo Wellcome Inc.
Five Moore Drive, PO 13398
Research Triangle Park, NC 27709
US

This person is:

- ☐ applicant only
☒ applicant and inventor
☐ inventor only (If this check-box is marked, do not fill in below.)

State (that is, country) of nationality:

US

State (that is, country) of residence:

US

This person is applicant for the purposes of:

☐ all designated States☐ all designated States except the United States of America☒ the United States of America only☐ the States indicated in the Supplemental Box

Name and address: (Family name followed by given name; for a legal entity, full official designation. The address must include postal code and name of country. The country of the address indicated in this Box is the applicant's State (that is, country) of residence if no State of residence is indicated below.)

This person is:

- ☐ applicant only
☐ applicant and inventor
☐ inventor only (If this check-box is marked, do not fill in below.)

State (that is, country) of nationality:

State (that is, country) of residence:

This person is applicant for the purposes of:

☐ all designated States☐ all designated States except the United States of America☐ the United States of America only☐ the States indicated in the Supplemental Box

Name and address: (Family name followed by given name; for a legal entity, full official designation. The address must include postal code and name of country. The country of the address indicated in this Box is the applicant's State (that is, country) of residence if no State of residence is indicated below.)

This person is:

- ☐ applicant only
☐ applicant and inventor
☐ inventor only (If this check-box is marked, do not fill in below.)

State (that is, country) of nationality:

State (that is, country) of residence:

This person is applicant for the purposes of:

☐ all designated States☐ all designated States except the United States of America☐ the United States of America only☐ the States indicated in the Supplemental Box

Name and address: (Family name followed by given name; for a legal entity, full official designation. The address must include postal code and name of country. The country of the address indicated in this Box is the applicant's State (that is, country) of residence if no State of residence is indicated below.)

This person is:

- ☐ applicant only
☐ applicant and inventor
☐ inventor only (If this check-box is marked, do not fill in below.)

State (that is, country) of nationality:

State (that is, country) of residence:

This person is applicant for the purposes of:

☐ all designated States☐ all designated States except the United States of America☐ the United States of America only☐ the States indicated in the Supplemental Box

Further applicants and/or further inventors are indicated on another continuation sheet

Box No.V DESIGNATION OF STATES

The following designations are hereby made under Rule 4.9(a) (mark the applicable check-boxes; at least one must be marked):

Regional Patent

- ☒ **AP ARIPO Patent:** GH Ghana, GM Gambia, KE Kenya, LS Lesotho, MW Malawi, SD Sudan, SL Sierra Leone, SZ Swaziland, UG Uganda, ZW Zimbabwe, and any other State which is a Contracting State of the Harare Protocol and of the PCT
- ☒ **EA Eurasian Patent:** AM Armenia, AZ Azerbaijan, BY Belarus, KG Kyrgyzstan, KZ Kazakhstan, MD Republic of Moldova, RU Russian Federation, TJ Tajikistan, TM Turkmenistan, and any other State which is a Contracting State of
- ☒ **EP European Patent:** AT Austria, BE Belgium, CH and LI Switzerland and Liechtenstein, CY Cyprus, DE Germany, DK Denmark, ES Spain, FI Finland, FR France, GB United Kingdom, GR Greece, IE Ireland, IT Italy, LU Luxembourg, MC Monaco, NL Netherlands, PT Portugal, SE Sweden, and any other State which is a Contracting State of the European Patent Convention and of the PCT
- ☒ **OA OAPI Patent:** BF Burkina Faso, BJ Benin, CF Central African Republic, CG Congo, CI Côte d'Ivoire, CM Cameroon, GA Gabon, GN Guinea, GW Guinea-Bissau, ML Mali, MR Mauritania, NE Niger, SN Senegal, TD Chad, TG Togo, and any other State which is a member State of OAPI and a Contracting State of the PCT (if other kind of protection or treatment desired, specify on dotted line)

National Patent (if other kind of protection or treatment desired, specify on dotted line):

- | | |
|---|--|
| <input checked="" type="checkbox"/> AE United Arab Emirates | <input checked="" type="checkbox"/> LR Liberia |
| <input checked="" type="checkbox"/> AL Albania | <input checked="" type="checkbox"/> LS Lesotho |
| <input checked="" type="checkbox"/> AM Armenia | <input checked="" type="checkbox"/> LT Lithuania |
| <input checked="" type="checkbox"/> AT Austria | <input checked="" type="checkbox"/> LU Luxembourg |
| <input checked="" type="checkbox"/> AU Australia | <input checked="" type="checkbox"/> LV Latvia |
| <input checked="" type="checkbox"/> AZ Azerbaijan | <input checked="" type="checkbox"/> MD Republic of Moldova |
| <input checked="" type="checkbox"/> BA Bosnia and Herzegovina | <input checked="" type="checkbox"/> MG Madagascar |
| <input checked="" type="checkbox"/> BB Barbados | <input checked="" type="checkbox"/> MK The former Yugoslav Republic of Macedonia |
| <input checked="" type="checkbox"/> BG Bulgaria | |
| <input checked="" type="checkbox"/> BR Brazil | <input checked="" type="checkbox"/> MN Mongolia |
| <input checked="" type="checkbox"/> BY Belarus | <input checked="" type="checkbox"/> MW Malawi |
| <input checked="" type="checkbox"/> CA Canada | <input checked="" type="checkbox"/> MX Mexico |
| <input checked="" type="checkbox"/> CH and LI Switzerland and Liechtenstein | <input checked="" type="checkbox"/> NO Norway |
| <input checked="" type="checkbox"/> CN China | <input checked="" type="checkbox"/> NZ New Zealand |
| <input checked="" type="checkbox"/> CU Cuba | <input checked="" type="checkbox"/> PL Poland |
| <input checked="" type="checkbox"/> CZ Czech Republic | <input checked="" type="checkbox"/> PT Portugal |
| <input checked="" type="checkbox"/> DE Germany | <input checked="" type="checkbox"/> RO Romania |
| <input checked="" type="checkbox"/> DK Denmark | <input checked="" type="checkbox"/> RU Russian Federation |
| <input checked="" type="checkbox"/> EE Estonia | <input checked="" type="checkbox"/> SD Sudan |
| <input checked="" type="checkbox"/> ES Spain | <input checked="" type="checkbox"/> SE Sweden |
| <input checked="" type="checkbox"/> FI Finland | <input checked="" type="checkbox"/> SG Singapore |
| <input checked="" type="checkbox"/> GB United Kingdom | <input checked="" type="checkbox"/> SI Slovenia |
| <input checked="" type="checkbox"/> GD Grenada | <input checked="" type="checkbox"/> SK Slovakia |
| <input checked="" type="checkbox"/> GE Georgia | <input checked="" type="checkbox"/> SL Sierra Leone |
| <input checked="" type="checkbox"/> GH Ghana | <input checked="" type="checkbox"/> TJ Tajikistan |
| <input checked="" type="checkbox"/> GM Gambia | <input checked="" type="checkbox"/> TM Turkmenistan |
| <input checked="" type="checkbox"/> HR Croatia | <input checked="" type="checkbox"/> TR Turkey |
| <input checked="" type="checkbox"/> HU Hungary | <input checked="" type="checkbox"/> TT Trinidad and Tobago |
| <input checked="" type="checkbox"/> ID Indonesia | <input checked="" type="checkbox"/> UA Ukraine |
| <input checked="" type="checkbox"/> IL Israel | <input checked="" type="checkbox"/> UG Uganda |
| <input checked="" type="checkbox"/> IN India | <input checked="" type="checkbox"/> US United States of America |
| <input checked="" type="checkbox"/> IS Iceland | Continuation-in-part |
| <input checked="" type="checkbox"/> JP Japan | <input checked="" type="checkbox"/> UZ Uzbekistan |
| <input checked="" type="checkbox"/> KE Kenya | <input checked="" type="checkbox"/> VN Viet Nam |
| <input checked="" type="checkbox"/> KG Kyrgyzstan | <input checked="" type="checkbox"/> YU Yugoslavia |
| <input checked="" type="checkbox"/> KP Democratic People's Republic of Korea | <input checked="" type="checkbox"/> ZA South Africa |
| | <input checked="" type="checkbox"/> ZW Zimbabwe |
| <input checked="" type="checkbox"/> KR Republic of Korea | Check-boxes reserved for designating States which have become party to the PCT after issuance of this sheet: |
| <input checked="" type="checkbox"/> KZ Kazakhstan | <input checked="" type="checkbox"/> .TZ United Republic of Tanzania |
| <input checked="" type="checkbox"/> LC Saint Lucia | <input checked="" type="checkbox"/> .DM Dominica |
| <input checked="" type="checkbox"/> LK Sri Lanka | <input checked="" type="checkbox"/> .CR Costa Rica |

Precautionary Designation Statement: In addition to the designations made above, the applicant also makes under Rule 4.9(b) all other designations which would be permitted under the PCT except any designation(s) indicated in the Supplemental Box as being excluded from the scope of this statement. The applicant declares that those additional designations are subject to confirmation and that any designation which is not confirmed before the expiration of 15 months from the priority date is to be regarded as withdrawn by the applicant at the expiration of that time limit. (Confirmation of a designation consists of the filing of a notice specifying that designation and the payment of the designation and confirmation fees. Confirmation must reach the receiving Office within the 15-month time limit.)

Supplemental Box

If the Supplemental Box is not used, this sheet need not be included in the request.

1. If, in any of the Boxes, the space is insufficient to furnish all the information: in such case, write "Continuation of Box No. ..." [indicate the number of the Box] and furnish the information in the same manner as required according to the captions of the Box in which the space was insufficient, in particular:

- (i) if more than two persons are involved as applicants and/or inventors and no "continuation sheet" is available: in such case, write "Continuation of Box No. III" and indicate for each additional person the same type of information as required in Box No. III. The country of the address indicated in this Box is the applicant's State (that is, country) of residence if no State of residence is indicated below;
- (ii) if, in Box No. II or in any of the sub-boxes of Box No. III, the indication "the States indicated in the Supplemental Box" is checked: in such case, write "Continuation of Box No. II" or "Continuation of Box No. III" or "Continuation of Boxes No. II and No. III" (as the case may be), indicate the name of the applicant(s) involved and, next to (each) such name, the State(s) (and/or, where applicable, ARIPO, Eurasian, European or OAPI patent) for the purposes of which the named person is applicant;
- (iii) if, in Box No. II or in any of the sub-boxes of Box No. III, the inventor or the inventor/applicant is not inventor for the purposes of all designated States or for the purposes of the United States of America: in such case, write "Continuation of Box No. II" or "Continuation of Box No. III" or "Continuation of Boxes No. II and No. III" (as the case may be), indicate the name of the inventor(s) and, next to (each) name, the State(s) (and/or, where applicable, ARIPO, Eurasian, European or OAPI patent) for the purposes of which the named person is inventor;
- (iv) if, in addition to the agent(s) indicated in Box IV, there are further agents: in such case, write "Continuation of Box No. IV" and indicate for each further agent the same type of information as required in Box No. IV;
- (v) if, in Box No. V, the name of any State (or OAPI) is accompanied by the indication "patent of addition," or "certificate of addition," or if, in Box No. V., the name of the United States of America is accompanied by an indication "continuation" or "continuation-in-part": in such case, write "Continuation of Box No. V" and the name of each State involved (or OAPI), and after the name of each such State (or OAPI), the number of the parent title or parent application and the date of grant of the parent title or filing of the parent application;
- (vi) if, in Box No. VI, there are more than three earlier applications whose priority is claimed: in such case, write "Continuation of Box No. VI" and indicate for each additional earlier application the same type of information as required in Box No. VI;
- (vii) if, in Box No. VI, the earlier application is an ARIPO application: in such case, write "Continuation of Box No. VI", specify the number of the item corresponding to that earlier application and indicate at least one country party to the Paris Convention for the Protection of Industrial Property for which that earlier application was filed.

2. If, with regard to the precautionary designation statement contained in Box No. V, the applicant wishes to exclude any State(s) from the scope of that statement: in such case, write "Designation(s) excluded from precautionary designation statement" and indicate the name or two-letter code of each State so excluded.

3. If the applicant claims, in respect of any designated Office, the benefits of provisions of the national law concerning non-prejudicial disclosures or exceptions to lack of novelty: in such case, write "Statement concerning non-prejudicial disclosures or exceptions to lack of novelty" and furnish that statement below.


Continuation of Box IV:

HESKETH, Alan (GB); CRAWLEY, Karen (GB); DOLTON, Peter I. (GB); DAWSON, Hugh B. (GB); FILLER, Wendy Anne. (GB); HACKETT, Ruth Elizabeth (GB); HAMMETT, Audrey G. C. (GB); LANE, Graham M. H. (GB); LEAROYD, Stephanie Anne (GB); QUILLIN, Helen Kaye (GB); REED, Michael A. (GB); REES, Marion (GB); STOTT, Michael John (GB); TEUTEN, Andrew J. (GB); THORNLEY, Rachel M. (GB) and VOLCKMAN, Janis Florence (GB) all in c/o Glaxo Wellcome plc., Glaxo Wellcome House, Berkeley Avenue, Greenford, Middlesex, UB6 0NN, GB

Continuation of Box V

United States of America: Provisional 60/100,491; 16 September 1998 (16/09/98)

United States of America: Provisional 60/100,704; 17 September 1998 (17/09/98)

Box No. VI PRIORITY CLAIM		<input type="checkbox"/> Further priority claims are indicated in the Supplemental Box.		
Filing date of earlier application (day/month/year)	Number of earlier application	Where earlier application is:		
		national application: country	regional application:* regional Office	international application: receiving Office
item (1) 16/09/98 16 September 1998	60/100,491	US		
item (2) 17/09/98 17 September 1998	60/100,704	US		
item (3)				
<input checked="" type="checkbox"/> The receiving Office is requested to prepare and transmit to the International Bureau a certified copy of the earlier application(s) (only if the earlier application was filed with the Office which for the purposes of the present international application is the receiving Office) identified above as item(s): (1) (2) <small>* Where the earlier application is an ARIPO application, it is mandatory to indicate in the Supplemental Box at least one country party to the Paris Convention for the Protection of Industrial Property for which that earlier application was filed (Rule 4.10(b)(ii)). See Supplemental Box.</small>				
Box No. VII INTERNATIONAL SEARCHING AUTHORITY				
Choice of International Searching Authority (ISA) (if two or more International Searching Authorities are competent to carry out the international search, indicate the Authority chosen; the two-letter code may be used):		Request to use results of earlier search; reference to that search (if an earlier search has been carried out by or requested from the International Searching Authority): Date (day/month/year) Number Country (or regional Office)		
ISA/us				
Box No. VIII CHECK LIST: LANGUAGE OF FILING				
This international application contains the following number of sheets: request : 5 description (excluding sequence listing part) : 7 claims : 2 abstract : 1 drawings : 3 sequence listing part of description : 0 Total number of sheets : 18		This international application is accompanied by the item(s) marked below: 1. <input checked="" type="checkbox"/> fee calculation sheet 2. <input checked="" type="checkbox"/> separate signed power of attorney 3. <input type="checkbox"/> copy of general power of attorney; reference number, if any: 4. <input checked="" type="checkbox"/> statement explaining lack of signature 5. <input type="checkbox"/> priority document(s) identified in Box No. VI as item(s): 6. <input type="checkbox"/> translation of international application into (language): 7. <input type="checkbox"/> separate indications concerning deposited microorganism or other biological material 8. <input type="checkbox"/> nucleotide and/or amino acid sequence listing in computer readable form 9. <input checked="" type="checkbox"/> other (specify): copy of POA giving DJL right to sign for Glaxo Group Limited		
Figure of the drawings which should accompany the abstract: 1		Language of filing of the international application: English		
Box No. IX SIGNATURE OF APPLICANT OR AGENT				
Next to each signature, indicate the name of the person signing and the capacity in which the person signs (if such capacity is not obvious from reading the request).				
 Elizabeth Selby Attorney of Record				

For receiving Office use only		2. Drawings: <input type="checkbox"/> received: <input type="checkbox"/> not received:
1. Date of actual receipt of the purported international application:		
3. Corrected date of actual receipt due to later but timely received papers or drawings completing the purported international application:		
4. Date of timely receipt of the required corrections under PCT Article 11(2):		
5. International Searching Authority (if two or more are competent): ISA/	6. <input type="checkbox"/> Transmittal of search copy delayed until search fee is paid	

For International Bureau use only
Date of receipt of the record copy by the International Bureau:

PCT

FEE CALCULATION SHEET

Annex to the Request

For receiving Office use only

International application No.

Date stamp of the receiving Office

Applicant's or agent's
file reference

PU3562WO

Applicant
Glaxo Group Limited

CALCULATION OF PRESCRIBED FEES

1. TRANSMITTAL FEE

240.00

T

2. SEARCH FEE

700.00

S

International search to be carried out by ISA/US

(If two or more International Searching Authorities are competent in relation to the international application, indicate the name of the Authority which is chosen to carry out the international search.)

3. INTERNATIONAL FEE

Basic Fee

The international application contains 18 sheets.

first 30 sheets 455.00 b₁

0 x \$0.00 = 0.00 b₂
remaining sheets additional amount

Add amounts entered at b₁ and b₂ and enter total at B 455.00 B

Designation Fees

The international application contains 104 designations.

10 x 105.00 = 1,050.00 D
number of designation fees amount of designation fee

payable (maximum 10)

Add amounts entered at B and D and enter total at I 1,505.00 I

(Applicants from certain States are entitled to a reduction of 75% of the international fee. Where the applicant is (or all applicants are) so entitled,

4. FEE FOR PRIORITY DOCUMENT (if applicable) 30.00 P

5. TOTAL FEES PAYABLE

Add amounts entered at T, S, I and P, and enter total in the TOTAL box

2,475.00

TOTAL

☐ The designation fees are not paid at this time.

MODE OF PAYMENT

☒ authorization to charge
deposit account (see below)

☐ bank draft

☐ coupons

☐ cheque

☐ cash

☐ other (specify):

☐ postal money order

☐ revenue stamps

DEPOSIT ACCOUNT AUTHORIZATION (this mode of payment may not be available at all receiving Offices)

The RO/ US ☒ is hereby authorized to charge the total fees indicated above to my deposit account.

☒ (this check-box may be marked only if the conditions for deposit accounts of the receiving Office so permit) is hereby authorized to charge any deficiency or credit any overpayment in the total fees indicated above to my deposit account.

☒ is hereby authorized to charge the fee for preparation and transmittal of the priority document to the International Bureau of WIPO to my deposit account.

07-1392

14 September 1999

Elizabeth Keller

Deposit Account Number

Date (day/month/year)

Signature